Biomarker-based Pipelines


Solid tumors

소화기암,기타 고형암
  • About ADC

    • ADC is a next-generation anti-cancer drug called "Magic Bullet" with low side effects and high efficacy
    • ADC overcomes the limitations of current treatments and the market size is expected to continue to grow
    • By conjugating suitable anti-cancer drugs to antibodies, ADCs can be applied to novel treatment options for various solid cancers
  • Mode of Action

    • ED2 is specifically expressed on the cell surface of cancer-associated fibroblasts (CAFs) in the tumor microenvironment of colon cancer, and it promotes cancer cell proliferation and invasion.
    • ED2 antibody-drug conjugates bind to ED2, enter into the cell, and then cytotoxic substances are released by specific enzymatic cleavage reaction, ultimately leading to the destruction of cancer-associated fibroblasts or cancer cells.
  • Core Competitiveness

    • Target feasibility confirmed in animal models and human specimen
    • Antibody candidates ready to be applicable for Drug conjugation are in hands
    • In vitro and in vivo assay systems are established

Development Status

Efficacy study with ED2 ADC candidates